Key Developments: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

105.55USD
19 Dec 2014
Price Change (% chg)

$-1.26 (-1.18%)
Prev Close
$106.81
Open
$106.63
Day's High
$107.39
Day's Low
$105.50
Volume
19,154,418
Avg. Vol
8,402,700
52-wk High
$109.49
52-wk Low
$86.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson announces acceptance of binding offer from The Carlyle Group to acquire ortho-clinical diagnostics
Monday, 31 Mar 2014 07:45am EDT 

Johnson & Johnson:Accepts the binding offer from The Carlyle Group, which was received and announced on Jan. 16 to acquire its Ortho-Clinical Diagnostics business for about $4 bln.The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.  Full Article

Maharashtra FDA cancels Johnson & Johnson's India’s licence-Business Standard
Thursday, 20 Mar 2014 02:34pm EDT 

Johnson & Johnson:The Maharashtra’s Food and Drug Administration (FDA) has scrapped Johnson & Johnson India’s licence to make cosmetics at its unit in Mulund, a Mumbai suburb-Business Standard.The order was issued by the joint commissioner on March 15 while giving time till April 21 to appeal the decision.The company has been held responsible for the violation of the Drugs & Cosmetic Act and the rules framed in 1945.A J&J India spokesman said, 'It is inappropriate to comment since the matter is sub judice.  Full Article

Reckitt Benckiser Group Plc to acquire global rights to K-Y brand from Johnson & Johnson subsidiary, McNEIL-PPC Inc
Monday, 10 Mar 2014 04:20am EDT 

Reckitt Benckiser Group Plc:Signs definitive agreement to acquire the global rights to the K-Y brand from McNEIL-PPC Inc, a subsidiary of Johnson & Johnson.Transaction is expected to close in mid 2014.No employees or fixed assets are included in the purchase.  Full Article

Louisiana's court rules for Johnson & Johnson in appeal of Risperdal suit - Reuters
Tuesday, 28 Jan 2014 04:52pm EST 

Johnson & Johnson:won an appeal in Louisiana Supreme Court on Jan. 28 over its marketing of anti-psychotic drug Risperdal as the court overturned a ruling that would have imposed a $258 million penalty on the company - Reuters.The ruling said that the Louisiana Attorney General, James Caldwell, failed to prove that Janssen Pharmaceutical Inc, part of J&J, violated state law when it misrepresented through off-label statements the potential risk of side effects of the drug.The Louisiana case was not part of a broader $2.2 billion settlement that J&J had made last fall with the U.S. Department of Justice regarding marketing practices for the drug.  Full Article

Johnson & Johnson gives FY 2014 EPS guidance
Tuesday, 21 Jan 2014 07:45am EST 

Johnson & Johnson:Sees FY 2014 of $5.75 to $5.85 per share, which excludes the impact of special items.FY 2014 EPS of $5.85 - Thomson Reuters I/B/E/S.  Full Article

U.S. FDA panel rejects Johnson & Johnson drug for acute coronary syndrome-Reuters
Thursday, 16 Jan 2014 05:32pm EST 

Johnson & Johnson:Says that its anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Jan 16-Reuters.Says panel voted 10 to 0, with one abstention, that data presented by the company from a single clinical trial was not strong enough to justify approval, especially since some data from was missing.Says.  Full Article

Carlyle Group LP agrees to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics for $4.15 bln
Thursday, 16 Jan 2014 07:45am EST 

Carlyle Group LP:Says it has agreed to acquire Johnson & Johnson`s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 bln.Says the transaction is subject to customary regulatory approvals and is expected to close in the middle of 2014.  Full Article

Johnson & Johnson announces quarterly dividend
Thursday, 2 Jan 2014 08:30am EST 

Johnson & Johnson:Says it has declared a cash dividend for the first quarter of 2014 of $0.66 per share on the company's common stock.Says the dividend is payable on Mar. 11 to shareholders of record at the close of business on Feb. 25.Says the ex-dividend date is Feb. 21.  Full Article

EU regulators fine Johnson & Johnson, Novartis AG 16 mln euros for generic drug deal - Reuters
Tuesday, 10 Dec 2013 09:00am EST 

Johnson & Johnson and Novartis AG:European Union antitrust regulators fined Johnson & Johnson .N and Novartis AG a total of 16 million euros ($21.95 million) on Dec. 10 for blocking the sale of a generic painkiller in the Dutch market - Reuters.The European Commission said in a statement that the deal between the two companies meant patients did not have access to the cheaper generic version of fentanyl for 17 months starting from July 2005.Johnson & Johnson and its Dutch unit, Janssen-Cilag, were fined 10.8 million euros while Novartis and its Dutch subsidiary, Sandoz, were fined 5.5 million euros.  Full Article

Johnson & Johnson's Unit To Pay $2.5 Billion In U.S. Hip Implant Settlement-Reuters
Tuesday, 19 Nov 2013 05:18pm EST 

Reuters reported that a unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the Company’s artificial hip implants. The settlement would compensate an estimated 8,000 patients who underwent surgery to replace their hip implants, according to a statement from Johnson & Johnson unit Depuy Orthopaedics Inc and lawyers for the plaintiffs.  Full Article

Galapagos loses partner on inflammatory bowel drug

BRUSSELS - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

Search Stocks